Around 4% of the population naturally lack the receptor named NKG2C, and in 30% of the population this receptor is only partially available, which could be responsible for severe COVID-19. The receptor communicates with an infected cell via one of its specialized surface structures, HLA-E. The course and severity of COVID-19 in individual patients is largely influenced by the interaction between the SARS-CoV-2 coronavirus and the human immune system.
‘NK cell response should be the target for drugs that could help prevent severe COVID-19 disease.’
Read More..Tweet it Now
Normally, the antiviral immune response of natural killer cells (NK cells) is an important step in combating viral replication in the early phase of the infection.Read More..
A research group from the Center for Virology at the Medical University of Vienna, led by Elisabeth Puchhammer-Stöckl, has now shown, in collaboration with doctors from Klinik Favoriten, that people with a partial or total absence of the NKG2C receptor are most likely to develop severe COVID-19.
In their study, which was recently published in the journal Genetics in Medicine, the authors showed that people who required hospitalization with COVID-19 were significantly more likely to exhibit the genetic variation underlying the lack of the receptor than people who only experienced mild disease.
Puchhammer-Stöckl explains: "Absence of the receptor was particularly prevalent in COVID-19 patients being treated in intensive care units, irrespective of age or gender. Genetic variations on the HLA-E of the infected cell were also associated with disease severity, albeit to a lesser extent."
The current study therefore shows the major importance of NK-cell response in the battle against SARS-CoV-2 infection: "This part of the immune response could therefore also represent an important target for drugs that could help to prevent severe COVID-19 disease," explains the MedUni Vienna expert.
Advertisement
Source-Eurekalert